About Spliceosome RNA helicase DDX39B
Spliceosome RNA helicase DDX39B (DDX39B) is a protein
from Homo sapiens identified by UniProt accession
Q13838, 428 residues long.
MolForge cross-references it against 0 known binders and
98 disease associations.
Target properties
| Protein name | Spliceosome RNA helicase DDX39B |
|---|
| UniProt accession | Q13838 |
|---|
| Gene | DDX39B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 428 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (98)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.55
- Alzheimer disease · score 0.50
- multiple sclerosis · score 0.50
- lysosomal storage disease · score 0.50
- Parkinson disease · score 0.50
- lymphocyte count · score 0.38
- leukocyte count · score 0.37
- neuroinflammatory disorder · score 0.37
- monocyte count · score 0.29
- mean corpuscular hemoglobin · score 0.23
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q13838-F1 | alphafold | PREDICTED | 84.81 | — |
Amino-acid sequence (428 residues)
MAENDVDNEL LDYEDDEVET AAGGDGAEAP AKKDVKGSYV SIHSSGFRDF LLKPELLRAI VDCGFEHPSE VQHECIPQAI LGMDVLCQAK SGMGKTAVFV LATLQQLEPV TGQVSVLVMC HTRELAFQIS KEYERFSKYM PNVKVAVFFG GLSIKKDEEV LKKNCPHIVV GTPGRILALA RNKSLNLKHI KHFILDECDK MLEQLDMRRD VQEIFRMTPH EKQVMMFSAT LSKEIRPVCR KFMQDPMEIF VDDETKLTLH GLQQYYVKLK DNEKNRKLFD LLDVLEFNQV VIFVKSVQRC IALAQLLVEQ NFPAIAIHRG MPQEERLSRY QQFKDFQRRI LVATNLFGRG MDIERVNIAF NYDMPEDSDT YLHRVARAGR FGTKGLAITF VSDENDAKIL NDVQDRFEVN ISELPDEIDI SSYIEQTR
Explore Spliceosome RNA helicase DDX39B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets